1. Home
  2. SOTK vs IFRX Comparison

SOTK vs IFRX Comparison

Compare SOTK & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sono-Tek Corporation

SOTK

Sono-Tek Corporation

HOLD

Current Price

$4.94

Market Cap

73.7M

Sector

Technology

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$2.41

Market Cap

66.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOTK
IFRX
Founded
1975
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.7M
66.0M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
SOTK
IFRX
Price
$4.94
$2.41
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
N/A
$6.25
AVG Volume (30 Days)
32.9K
3.0M
Earning Date
05-27-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
37.50
N/A
EPS
0.11
N/A
Revenue
$20,909,315.00
N/A
Revenue This Year
$4.02
N/A
Revenue Next Year
$10.95
N/A
P/E Ratio
$59.31
N/A
Revenue Growth
1.97
N/A
52 Week Low
$3.23
$0.74
52 Week High
$5.70
$2.95

Technical Indicators

Market Signals
Indicator
SOTK
IFRX
Relative Strength Index (RSI) 52.02 56.28
Support Level $3.88 $0.96
Resistance Level $5.15 $2.95
Average True Range (ATR) 0.32 0.22
MACD -0.03 -0.05
Stochastic Oscillator 35.03 20.86

Price Performance

Historical Comparison
SOTK
IFRX

About SOTK Sono-Tek Corporation

Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: